Skip to main content
. Author manuscript; available in PMC: 2013 Apr 25.
Published in final edited form as: J Nucl Med. 2012 Mar 1;53(4):567–574. doi: 10.2967/jnumed.111.094425

Figure 3.

Figure 3

GLUT4 immunohistochemical (A) and 18F-FDG PET (B) studies of patient with primary gastric GIST before and 8 wk after imatinib mesylate therapy. GLUT4 intense brown staining at baseline is no longer apparent on week 8 surgical specimen. 18F-FDG PET images show intense 18F-FDG uptake in the gastric mass before treatment and resolution at week 8.